Skip to main content
. Author manuscript; available in PMC: 2023 Aug 31.
Published in final edited form as: Annu Rev Genomics Hum Genet. 2022 May 10;23:449–473. doi: 10.1146/annurev-genom-111621-102737

Figure 6.

Figure 6

Percentage of thiopurine-naive patients diagnosed with acute lymphocytic leukemia who had a known TPMT and NUDT15 genotype prior to initiating thiopurine therapy at St. Jude Children’s Research Hospital, by quarter. TPMT genotyping was implemented prior to 2012; NUDT15 genotyping was implemented clinically in 2017. The goal quality metric is 100% for the top curve and 0% for the bottom curve. Approximately 22 patients per quarter were included in this metric.